TBPH

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.

NEW YORK, June 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Theravance Biopharma, Inc. (NASDAQ: TBPH ) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00 per share in cash and (ii) one contingent value right.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Theravance and its board of directors violat.

MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​deal.

Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine within the next ten years Transaction follows a comprehensive strategic alternatives review conducted by the Company's Strategic Review Committee and Board of Directors Transaction expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions DUBLIN, June 29, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (Nasdaq: TBPH) today announced that it has entered into a definitive agreement pursuant to which Zymeworks Inc. will acquire the Company for $17.00 per share in cash, representing an equity value of approximately $929 million. In addition to the cash consideration, Theravance Biopharma shareholders will receive a CVR entitling them to 80% of net proceeds realized from any future license, divestiture or other monetization of ampreloxetine over the next ten years, with the remaining 20% to Zymeworks.

Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.